Molecular analysis of NTRK fusion-positive non-small-cell lung cancers showed no concurrent alterations in KRAS, EGFR, ALK, and ROS1 or other known oncogenic drivers22,23. Here, ROS1 is linked to non-small cell lung carcinoma.